Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26377963 | 0.76 | NR4A2 (0.60) | MAOBDCPSDAORAB9AMAOA | |
| SCHEMBL31172240 | 0.76 | KMT2A (0.60) | MEN1KMT2AMAOBSMN1; SMN2KDM4E | |
| SCHEMBL4638799 | 0.76 | KMT2A (0.60) | MEN1KMT2AMAOBSMN1; SMN2KDM4E | |
| SCHEMBL4639191 | 0.76 | MAOB (0.59) | MEN1KMT2AMAOBSMN1; SMN2MET | |
| SCHEMBL2983086 | 0.75 | MAOB (0.50) | MAOBDCPSDAORAB9AMAOA | |
| SCHEMBL13577150 | 0.74 | SMN1; SMN2 (0.53) | MEN1KMT2ASMN1; SMN2METKDM4E | |
| SCHEMBL3099735 | 0.74 | SMN1; SMN2 (0.53) | MEN1KMT2AMAOBSMN1; SMN2MET | |
| SCHEMBL157731 | 0.72 | MAOB (0.66) | MAOBMAOANR4A2 | |
| SCHEMBL13577127 | 0.72 | MAOB (0.66) | MAOBMAOANR4A2 | |
| SCHEMBL17788185 | 0.71 | MPO (0.41) | MEN1KMT2ASMN1; SMN2METKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501427-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | MEN1 1415/4885KMT2A 1365/4885MAOB 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.